PhaseBio Pharmaceuticals — Investor Presentation (May 2020)
28 slides from PhaseBio Pharmaceuticals's investor presentation, May 12, 2020
Slide 1: Corporate Overview
Corporate Overview PhaseBio aso
Slide 2: Legal Disclaimer
Legal Disclaimer This presentation includes forward-looking statements. All statements contained in this presentation other than statements of historical facts, including statements regarding future results of operations and financial position of PhaseBio Pharmaceuticals, Inc. (“we,” “us” or “our”)
Slide 3: Company Overview
Company Overview Therapeutic Clinical-stage biopharma company focused on the development and commercialization of novel therapies to treat cardiopulmonary diseases Focus Novel agent for immediate and sustained reversal of ticagrelor, the preferred antiplatelet therapy of the American College of PB24
Slide 4: A Clinical Stage, Cardiopulmonary Focused Biopharmaceutical Company
A Clinical Stage, Cardiopulmonary Focused Biopharmaceutical Company Program Pre-Clinical Phase 1 Phase 2 Phase 3 Commercial Rights Upcoming Milestone PB2452 Phase 3 ongoing 2H 2020 Reversal of Ticagrelor Targeting to submit BLA in 2H22* Target for publication of Antiplatelet Activity Phase 2a trial
Slide 5: Corporate
Corporate CONFIDENTIAL
Slide 6: Creating Value for Stakeholders in 2020
Creating Value for Stakeholders in 2020 • Following a successful 2019, PhaseBio continues a rapid pace of development and execution in 2020 Announced innovative funding and co-development collaboration for PB2452 with SFJ Pharmaceuticals Bolstered pipeline with acquisition of resistant hypertens
Slide 7: First-Quarter 2020 Financial Highlights
First-Quarter 2020 Financial Highlights • Operating expense: $14.6M - R&D: $11.4M - SG&A: $3.2M • Loss from Operations: ($14.3M) • Net Loss of ($14.9M) or ($0.52) per share - 28.8M shares used for computing Q1 2020 net loss per share • Cash and cash equivalents as of 03/31/2020: $59.4M CONFIDENTIAL
Slide 8: Experienced Management Team
Experienced Management Team JONATHAN MOW SUSAN ARNOLD, PhD JIM BALLANCE, PhD GLEN BURKHARDT Chief Executive Officer VP of Preclinical & CMC VP Research & Scientific Affairs VP Human Resources KRIS HANSON JOHN LEE, MD, JOHN SHARP MICHAEL YORK VP Legal PhD, FACC Chief Financial Officer VP Corp Develop
Slide 9: Reversal Agent for Ticagrelor
PB2452 Reversal Agent for Ticagrelor CONFIDENTIAL
Slide 10: PB2452: Novel Reversal Agent for Brilinta (Ticagrelor)
PB2452 PB2452: Novel Reversal Agent for Brilinta (Ticagrelor) • Within the P2Y12 antagonist class of oral antiplatelet therapies, ticagrelor has proven superiority vs. clopidogrel, and a unique reversible binding profile - Clopidogrel and prasugrel, the other members of the oral P2Y12 antagonist cla
Slide 11: PB2452: Well-Characterized Mechanism of Reversal of Ticagrelor
PB2452 PB2452: Well-Characterized Mechanism of Reversal of Ticagrelor 1. ADP binds to P2Y12 3. PB2452 binds to free ticagrelor 5. As free ticagrelor is eliminated, ADP can again receptor causing with very high affinity activate the P2Y12 receptor, restoring platelet platelet aggregation activity Thi
Slide 12: PB2452: Development and Regulatory Timelines
PB2452 PB2452: Development and Regulatory Timelines 2019 2020 2021 2022 2023 NEJM Phase 2a Phase 2b: Older and elderly subjects N=200, 150 randomized to receive PB2452 Breakthrough FDA EMA PRIME Phase 3 Interim Analysis for Accelerated Approval Post-approval completion of Phase 3 Therapy EOP1 Design
Slide 13: PB2452 Phase 1 Proof-of-Concept Study in Healthy Subjects
PB2452 PB2452 Phase 1 Proof-of-Concept Study in Healthy Subjects • Randomized, double-blind, placebo-controlled, single ascending dose, sequential group study (n=64) • Platelet function evaluated using three well established and commonly used assays: LTA, VerifyNow PRUTest® and VASP - Results from a
Slide 14: Normalized Platelet Function After Ticagrelor Reversal
PB2452 Normalized Platelet Function After Ticagrelor Reversal VerifyNow PRUTest Normal Platelet Function: Inhibited Platelet Function: Return to Normal Platelet Pre-Ticagrelor Dosing Post-Ticagrelor Dosing Function: Post-PB2452 Dosing Normal Platelet Function Inhibited Platelet Function Platelet Rea
Slide 15: Positive Preliminary PB2452 Phase 2a Results
PB2452 Positive Preliminary PB2452 Phase 2a Results • Positive preliminary results from the PB2452 Phase 2a trial were disclosed via press release1 - First trial of PB2452 to include older and elderly subjects (ages 50-80) on dual antiplatelet therapy (DAPT) of ticagrelor and low-dose aspirin - Subj
Slide 16: PB2452 Regulatory Updates
PB2452 PB2452 Regulatory Updates Development plan for PB2452 designed with objective to broadly support global regulatory filings Separate written guidance from FDA and EMA indicates that a single, non-randomized, open-label Phase 3 trial of PB2452 in both surgical and major bleeding populations has
Slide 17: PB2452 Pivotal Phase 3 Trial Overview
PB2452 PB2452 Pivotal Phase 3 Trial Overview • Phase 3 trial is a key element of development plan that has garnered FDA Breakthrough Therapy and EMA PRIME designations • Open-label, single-arm study of reversal of the antiplatelet effects of ticagrelor with PB2452 in patients who present with uncont
Slide 18: SFJ Pharmaceuticals Funding and Co-Development Collaboration
PB2452 SFJ Pharmaceuticals Funding and Co-Development Collaboration • Innovative collaboration between SFJ and PhaseBio to support the global development of PB2452 • SFJ will fund up to $120 million to support the clinical development of PB2452 - SFJ has extensive experience in the global clinical d
Slide 19: Expect Continued Long-Term Rx Growth of Ticagrelor
PB2452 Expect Continued Long-Term Rx Growth of Ticagrelor PB2452 approval has the potential to drive continued positive momentum • Brilinta/Brilique sales in 2019 were $1.58B and growing (+20% Y/Y) - Patient growth drives Y/Y revenue growth in key regions: strong growth in the United States and Emer
Slide 20: PB1046 Once Weekly VIP Analog for Pulmonary Arterial Hypertension
PB1046 Once Weekly Vasoactive Intestinal Peptide (VIP) Analog for Pulmonary Arterial Hypertension
Slide 21: PB1046 High Unmet Need in an Orphan Disease
PB1046 High Unmet Need in an Orphan Disease Primary Pulmonary Arterial Hypertension (PAH, WHO Group 1 PH) • High unmet need for novel disease-modifying PAH therapies for greater efficacy - All 3 approved drug classes in PAH are vasodilators: prostacyclin, endothelin, and nitric oxide pathways - Pati
Slide 22: PB1046: Harnessing VIP to Create a Stable, Long-Acting Drug
PB1046 PB1046: Harnessing VIP to Create a Stable, Long-Acting Drug VIP as a THERAPEUTIC AGENT PRECLINICAL STUDIES Endogenous VIP PB1046 Support Clinical Development for: • Pulmonary Arterial Hypertension • DMD Cardiomyopathy • Heart Failure (Chemotherapy-Induced HF or HFpEF) • Cystic Fibrosis MECHAN
Slide 23: PB1046 Proprietary Elastin-Like Polypeptide (ELP) Technology
PB1046 Proprietary Elastin-Like Polypeptide (ELP) Technology Key to optimizing the profile of an injectable VIP product candidate PROLONGED CIRCULATING HALF-LIFE COACERVATION DELIVERS SLOW RELEASE “Biopolymer” Repeating Sequence of Human Elastin Peptides Outside Body Inside Body Active Moiety ↑ Temp
Slide 24: PB1046 Clinical Development Activities to Date
PB1046 PB1046 Clinical Development Activities to Date Have Supported Advancement into a Phase 2b PAH Efficacy Study PHASE 1 Studies Completed PAH PHASE 2 Studies SAD study in 4-week MAD study in Open-Label Phase 2a CardioMEMS in PAH Phase 2b PAH Efficacy hypertensive patients HFrEF patients on SOC s
Slide 25: PB6440 Aldosterone Synthase Inhibitor for Resistant Hypertension
PB6440 Aldosterone Synthase Inhibitor for Resistant Hypertension
Slide 26: PB6440 for Resistant Hypertension
PB6440 PB6440 for Resistant Hypertension • Upwards of 10 million patients in the United States have resistant hypertension and are at risk for serious, costly medical consequences (stroke, heart attack, kidney failure, etc.)1 • Physicians currently prescribe numerous combinations of antihypertensive
Slide 27: PB6440 Is Highly Selective for Aldosterone Synthase (CYP11B2)
PB6440 PB6440 Is Highly Selective for Aldosterone Synthase (CYP11B2) Selectivity and Potency Demonstrated in Primate Chronic Oral Dosing Model CYP11B Potency and Selectivity (IC50, µM) Human Monkey CYP11B2 CYP11B1# Selectivity CYP11B2 CYP11B1 Selectivity PB6440 0.024 4.859 202 0.016 5.802 363 LCI699
Slide 28: PhaseBio
PhaseBio
PhaseBio Pharmaceuticals — Investor Presentation (May 2020) on 6ix